Latest Asceneuron News & Updates

See the latest news and media coverage for Asceneuron. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Asceneuron

Biotechnology company developing treatments for neurodegenerative diseases

asceneuron.com
Headquarters
Lausanne, Switzerland
Founded year
2012
Company type
Private company
Number of employees
7–10

Last updated

Latest news about Asceneuron

In short: Asceneuron halted an Alzheimer's trial amid tau-targeting setbacks after raising $100 million to advance ASN51.

Company announcements

Asceneuron

Asceneuron appoints Barbara Angehrn Pavik as new CEO

Angehrn Pavik brings over 20 years of experience at Amgen, Onyx, Exelixis and Vifor. Outgoing CEO Dirk Beher becomes Chief Scientific Advisor as two compounds advance in clinical development.

Unlock all announcements with a

Media coverage

transkript

Asceneuron AG secures Series C financing

The Asceneuron AG from Lausanne has raised around USD 100 million to further develop its Phase II OGA inhibitor ASN51 for the treatment of Alzheimer's disease. The lead investor was Novo...

Unlock all articles with a

Never miss news about Asceneuron

Track Asceneuron and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.